CureVac announces 'positive' interim data on its COVID-19 vaccine candidate


CureVac has announced some "encouraging" data on its COVID-19 vaccine candidate.
The German company on Monday reported "positive interim data" on its potential coronavirus vaccine, saying it triggered an immune response during a phase one trial, Reuters reports.
"We are very encouraged by the interim Phase 1 data," CureVac CEO Franz-Werner Haas said. "It represents a critical milestone in our COVID-19 vaccine program and strongly supports the advancement of our vaccine candidate."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The company in a statement said during its ongoing phase one study, its vaccine candidate "was generally well tolerated across all tested doses," and it "induced strong binding and neutralizing antibody responses." The immune responses were "comparable to recovered COVID-19 patients," the company also said.
CureVac Chief Technology Officer Mariola Fotin-Mleczek said the initial data shows "a robust and highly efficient immune response," while lead investigator Peter Kremsner called the data "highly encouraging." The company plans to provide further details in the coming weeks, it said.
This experimental vaccine candidate from CureVac is taking the same approach as the ones being tested by Moderna and Pfizer, Reuters notes. CureVac is planning to begin the final stage of testing for its vaccine candidate before the end of 2020.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
A tall ship adventure in the Mediterranean
The Week Recommends Sailing aboard this schooner and exploring Portugal, Spain and Monaco is a 'magical' experience
-
How drone warfare works
The Explainer From Ukraine to Iran, it has become clear that unmanned aircraft are rapidly revolutionising modern warfare
-
The tourist flood in the Mediterranean: can it be stemmed?
Talking Point Finger-pointing at Airbnb or hotel owners obscures the root cause of overtourism in holiday hotspots: unmanageable demand
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia